Analyst Price Target is $28.00
▲ +4,136.01% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Atara Biotherapeutics in the last 3 months. The average price target is $28.00, with a high forecast of $28.00 and a low forecast of $28.00. The average price target represents a 4,136.01% upside from the last price of $0.66.
Current Consensus is
Hold
The current consensus among 3 contributing investment analysts is to hold stock in Atara Biotherapeutics. This Hold consensus rating has held steady for over two years.
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Read More